AIxBio RegistryAI molecules in the clinic

Does AI change the odds?

The question this registry exists to answer, and what the data can say so far.

The question

Most drugs that enter human trials never reach patients. Across the industry, about 1 in 13 candidates that start Phase 1 are eventually approved, and Phase 2 is the steepest step: fewer than 3 in 10 get through it.1

Developers that use AI say they choose better targets and design better molecules. If that is true, it should show up in the clinic as better odds at each phase, faster progress, or both. Testing the claim needs a denominator. It cannot be every molecule AI has touched: AI input is now routine across drug discovery, and much of it is never disclosed. What can be built is a cohort: the molecules dosed in people whose developers credit AI with choosing the target or producing the molecule, counted to a written definition, with what happened to each, including the programs that quietly stopped. Most published counts do not release their list. This registry does, so the comparison below can be checked and recomputed by anyone.

What the data can say so far

For each step, the bar under its name shows what has happened to the 75 strict-cohort molecules that reached it. The chart beside it compares the share that moved on with what published studies report for drug development as a whole.

Phase transitions: this registry's molecules against published industry estimates
  • Moved to the next phase
  • Stopped
  • Still running
  • This registry: share that moved on, with 95% CI
  • Industry: median of 5 studies
  • Range of the 5 studies

    The chart needs the registry data to load. The table below has the same figures.

    Show as a table
    StepReachedMoved onStoppedStill runningThis registry: moved on, of known outcomes (95% CI)Industry: median (range of 5 studies)
    StudyDataPhase 1 to 2Phase 2 to 3Phase 3 to filing

    Why it is too early to call

    What would settle it

    Outcomes, mainly from Phase 2. Several strict-cohort molecules are in Phase 2 or Phase 3 and still running. The registry checks their trial records every week and records what happens to them, and this page recomputes from the data each time.

    What these numbers suggest so far is argued in the companion essay, Turning the Crank Faster (Backed By Reality, 2 November 2026).

    How this is computed

    Sources

    1. BIO, Informa Pharma Intelligence and QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020. February 2021. 12,728 phase transitions; likelihood of approval from Phase 1, 7.9%.
    2. Jayatunga MKP et al. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discovery Today, 2024.
    3. Hay M et al. Clinical development success rates for investigational drugs. Nature Biotechnology 32:40–51, 2014. Data 2003–2011.
    4. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics 47:20–33, 2016. Compounds first tested in humans 1995–2007.
    5. Thomas DW et al. Clinical Development Success Rates 2006–2015. BIO, Biomedtracker and Amplion, 2016.
    6. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 20:273–286, 2019. Data 2000–2015.